We are live on ! Find out more
MAA

Mraz Amerine & Associates Portfolio holdings

AUM $697M
1-Year Est. Return 19.37%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+19.37%
3 Year Est. Return
+69.82%
5 Year Est. Return
+110.04%
10 Year Est. Return
+414.75%
AUM
$561M
AUM Growth
+$8.38M
Cap. Flow
-$6M
Cap. Flow %
-1.07%
Top 10 Hldgs %
61.11%
Holding
177
New
10
Increased
43
Reduced
75
Closed
11

Sector Composition

Rank Sector Weight
1 Financials 63.08%
2 Energy 10.58%
3 Industrials 2.85%
4 Technology 2.73%
5 Materials 1.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRO
176
DELISTED
Marathon Oil Corporation
MRO
-8,075
Closed -$215K
SWN
177
DELISTED
Southwestern Energy Company
SWN
-20,000
Closed -$142K

Similar funds

Mraz Amerine & Associates's Q4 2024 Portfolio in Review

As of Q4 2024, Mraz Amerine & Associates held 177 positions worth $561M, up 1.5% from $553M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Mraz Amerine & Associates's Q4 2024 filing shows 10 new, 43 increased, 75 reduced and 11 closed positions. Its largest new stake was Tesla: 1,015 shares worth $410K. The largest sale was Enstar Group, an estimated $9.21M.

By sector, the portfolio is most concentrated in Financials at 63% of assets, up from 62% a quarter earlier, followed by Energy and Industrials.

  • Mraz Amerine & Associates's largest Q4 2024 buy was Tesla: 1,015 shares worth $410K.
  • Mraz Amerine & Associates added most to Janus Henderson AAA CLO ETF in Q4 2024, an estimated $2.91M increase.
  • Mraz Amerine & Associates's biggest Q4 2024 reduction was Enstar Group, cutting an estimated $9.21M.
  • Mraz Amerine & Associates fully exited CVS Health in Q4 2024, selling an estimated $1.3M.
  • Mraz Amerine & Associates's ten largest holdings make up 61% of its $561M portfolio in Q4 2024.
  • Mraz Amerine & Associates opened 10 new positions and closed 11 in Q4 2024.
  • Mraz Amerine & Associates's portfolio value rose 1.5% quarter-over-quarter to $561M.

Based on Mraz Amerine & Associates's 13F filing for Q4 2024, filed 31 Jan 2025.